development pipeline includes: naloxone lotion for treatment of pruritus accompanying cutaneous T-cell lymphoma, a product with orphan drug and fast-track designations from the U.S. Food and Drug Administration; cidoxepin, a highly potent histamine H1-receptor antagonist being developed for relief of chronic urticaria; and a once-weekly tablet for nodulocystic acne.